Identification of pro-regenerative approaches to improve tendon healing is of critical importance given 30 the diminished quality of life and physical function that accompanies the typical fibrotic response to 31 tendon injury. S100a4 modulates fibrosis through tissue-type dependent mechanisms, and the role of 32 S100a4 in fibrotic, scar-mediated tendon healing has not been established. In the present study we 33 tested the hypothesis that inhibition of S100a4 improves tendon function following acute injury and 34
Introduction
Tendons are composed primarily of a dense, highly aligned collagen extracellular matrix (ECM), and 48 connect muscle to bone to transmit mechanical forces throughout the body. Following injury, tendon 49 demonstrates limited regenerative potential and heal through a scar-mediated fibrotic process involving 50 abundant, disorganized ECM deposition. While scar tissue can impart some mechanical strength to the 51 healing tissue, it is also mechanically inferior to native tendon and dramatically impairs normal tendon 52 function resulting in substantial morbidity. In addition, scar tissue increases tendon bulk and forms 53 adhesions to the surrounding tissues, impeding normal range of motion (ROM). This pathological 54 response to injury represents a major clinical burden considering there are over 300,000 surgical 55 tendon repairs in the United States annually (1), and up to 40% of primary flexor tendon repairs heal 56 with function limiting scar tissue (2). Despite this burden, there is currently no consensus biological or 57 pharmacological approach to improve tendon healing, due in large part to a paucity of information on 58 the cellular and molecular components involved. 59 60 S100a4 (also known as Fsp1, Mts1, Pk9a) is a member of the S100 family of EF-hand Ca 2+ -binding 61 proteins, and is a potent regulator of fibrosis in many tissues including the liver (3, 4), lung (5), heart (6) 62 and oral submucosa (7). An increase in the proportion of S100a4 + cells is characteristic of many 63 fibrotic conditions (5, 8), and elevated serum S100a4 levels positively correlate with fibrosis clinically 64 (4). Moreover, the therapeutic potential of S100a4 inhibition is suggested by S100a4-cell depletion 65 studies and S100a4 RNAi treatments in which fibrosis was halted, or effectively reversed (4, 9, 10). 66
While depletion of S100a4 + cells can inhibit fibrotic progression, S100a4 can also function as an intra-67 and extracellular signaling molecule to impact cellular processes including motility, survival, 68 differentiation, and contractility (11, 12) . Additionally, the effects of S100a4 are cell and tissue-type 69 dependent. We have previously shown that S100a4-Cre efficiently targets resident tendon cells (13), 70 however, the specific function of S100a4 and whether that function is cell-autonomous or cell-non-71 autonomous during scar-mediated fibrotic tendon healing is unknown. 72
In the present study we delineate the relative contributions of S100a4 expression and S100a4 + cells to 74 scar-mediated tendon healing and investigated both the cell non-autonomous extracellular signaling 75 function of S100a4, as well as the fate and function of S100a4-lineage cells. We have identified 76 S100a4 haploinsufficiency as a novel model of regenerative tendon healing and define a requirement 77
for S100a4
+ cells in the restoration of mechanical properties during tendon healing. These data identify 78 S100a4 as a novel target to improve tendon healing and demonstrate the efficacy of pharmacological 79 inhibition of S100a4 signaling to improve functional outcomes during healing. 80
81

Methods 82
Ethics statement: All animal studies were approved by the University of Rochester Committee for 83
Animal Resources. 84 85
Mouse strains: S100A4-GFP promoter mice (#012893), S100a4-TK (#012902), S100a4 GFP/+ (#012904), 86 S100a4-Cre (#012641), ROSA-Ai9 (#007909), and C57BL/6J (#000664) were acquired from The 87
Jackson Laboratory (Bar Harbor, ME). 88 S100a4-GFP promoter mice contain a construct encoding EGFP under control of the S100a4 promoter 89 sequence, resulting in green fluorescence in cells actively expressing S100a4 (14). 90 S100a4-TK mice contain a viral thymidine kinase gene downstream of the S100a4 promoter, and 91 treatment with the nucleoside analog ganciclovir (GCV) halts DNA replication in proliferating cells 92 expressing S100a4, resulting in apoptosis and S100a4 + cell ablation (9). Mice were treated twice per 93 day (i.p) with 75mg/kg GCV. S100a4 GFP/+ mice contain a GFP-encoding gene knocked into the exons 94 2-3 of the S100a4 gene, resulting in a 50% reduction in S100a4 protein expression (15). For RAGE 95 Antagonist Peptide (RAP) studies, C57BL/6J mice were treated with either 100µg RAP or vehicle (0.5% 96 bovine serum albumin in saline) via i.p. injection on D5-10 post-surgery. 97
98
Murine model of tendon injury and repair: Male and female mice aged 10-12 weeks underwent 99 complete transection and surgical repair of the flexor digitorum longus (FDL) tendon as previously 100 described (16). Mice were monitored and given analgesics post-operatively as needed. 101
Chromogen immunohistochemistry was performed on paraffin sections for S100a4 (1:20000, #197896, 130
Abcam, Cambridge MA), with a rabbit polymer kit (MP-7401, Vector Laboratories, Burlingame CA). 131
Immunofluorescence was carried out with the following primary and secondary antibodies: RAGE 132 Technologies, Carlsbad CA), and RNA extracted using the RNeasy mini kit (Qiagen, Germantown MD). 163
Quantitative PCR was performed for markers of M1 (iNOS, TNFa, CD86, CD64) and M2 (CD206, Arg1, 164 IL-1ra, CD163) polarization, and data normalized to b-actin expression.
166
Statistical analyses: Statistically significant differences between genotypes or treatments in in vitro and 167 in vivo studies were assessed by unequal variance unpaired t-test, with the exception of the S100a4 168 qPCR time-course, BMDM migration and polarization experiments, which were analyzed by one-way 169 ANOVA, followed by Tukey's multiple comparisons test. All analyses were conducted using GraphPad 170 
Results
174
S100a4 is expressed by resident tendon cells and the S100a4
+ population expands during healing. 175
Spatial localization of S100a4 was examined before and after tendon repair surgery in S100a4-Cre; 176 ROSA-Ai9 reporter mice to trace S100a4-lineage cells (S100a4 lin+ ; Fig. 1A & B) , and S100a4-177 GFP promoter mice to identify cells actively expressing S100a4 (S100a4 active+ ; Fig. 1C & D) . Most resident 178 tendon cells were S100a4 lin+ in the uninjured tendon. Following tendon repair, the S100a4-lineage 179 population expanded with S100a4 lin+ cells in the native and bridging scar tissue at D7 and D14 post-180 surgery (Fig. 1B) . Many resident tendon cells were actively expressing S100a4 at baseline, however 181 many S100a4 -cells were also present (Fig. 1D) . Following injury, the S100a4 active+ population also 182 expanded, with abundant S100a4 active+ cells in the bridging scar tissue from D3 to D14, with a marked 183 decrease by D28 (Fig. 1D) . Notably, the expansion of the S100a4 active+ population was also observed in 184 the healing Achilles tendon (Supplemental Fig. 1 ), suggesting potential conservation of S100a4 functionbetween tendons. Consistent with changes in spatial expression over time, S100a4 mRNA expression 186 increased from D3 to a peak at D10, followed by a progressive decline through D28 (Fig. 1E) . 187
188
S100a4 haploinsufficiency promotes regenerative, mechanically superior tendon healing 189
To determine the functional implications of decreasing S100a4 expression during tendon healing (Fig.  190 2A), we utilized S100a4 haploinsufficient mice (S100a4 GFP/+ ), which results in a 50% reduction in 191 S100a4 mRNA expression in the tendon (Fig. 2B) , as well as a robust decrease in S100a4 protein 192 expression during tendon healing (Fig. 2C ). Decreased S100a4 expression did not noticeably alter the 193 spatial localization of S100a4 + cells in either the un-injured tendon or at D14 post-surgery 194 (Supplemental Fig. 2 ). At D14 post-surgery, functional outcomes of scar formation in healing 195
S100a4
GFP/+ tendons were significantly improved compared to WT. A significant 36% increase in MTP 196
Flexion Angle was observed in S100a4 GFP/+ repairs, relative to WT (p=0.04) (Fig. 2D )
. Gliding 197
Resistance was significantly decreased by 43% in S100a4 GFP/+ repairs, relative to WT (p=0.028) (Fig.  198 2E), suggesting a reduction in scar formation in S100a4 GFP/+ repairs. In addition, maximum load at 199 failure was significantly increased (+35%) in S100a4 GFP/+ repairs relative to WT (p=0.003) (Fig. 2F ), 200 while stiffness was increased 28% in S100a4 GFP/+ repairs, relative to WT, however this increase was not 201 statistically significant (p=0.08) (Fig. 2G ). Taken together, these data suggest that S100a4 202 haploinsufficiency improves functional outcomes, while also improving tendon strength. 203
204
S100a4 knockdown improves tendon morphology and decreases myofibroblast content. 205
Morphologically, both ABHOG and picrosirius red staining demonstrate more highly aligned, mature 206 collagen fibers bridging the tendon ends in S100a4 haploinsufficient mice (blue arrows, Fig. 3A ). 207
Consistent with this, Col1a1 expression was significantly increased 5.6-fold (p=0.0095) in S100a4 GFP/+ 208 repairs, relative to WT repairs (Fig. 2B ), while no change in Col3a1 or Scx were observed between 209 groups ( Fig. 2C & D) . Expression of the myofibroblast marker α-SMA was decreased 2.4-fold in 210
S100a4
GFP/+ repairs, relative to WT (p=0.02) (Fig. 2E ). Consistent with this, a marked decrease in α-211 SMA protein was also observed in S100a4 GFP/+ repairs, relative to WT (white arrows, Fig. 3F ). Thesedata suggest that S100a4 haploinsufficiency promotes regenerative tendon healing via deposition of a 213 mature Col1 ECM and a decrease in pro-fibrotic myofibroblasts. 214
215
S100a4 modulates macrophage function. 216
Given the fibrotic nature of scar-mediated tendon healing, and the ability of macrophages to modulate 217 multiple aspects of the fibrotic process(20-23), we examined changes in macrophage content during 218 healing in S100a4 haploinsufficient mice, and changes in migration and polarization in response to 219 S100a4 in vitro. A substantial decrease in F4/80 + macrophages were observed in S100a4 GFP/+ repairs, 220 relative to WT (white arrows, Fig. 4A ), suggesting that knock-down of S100a4 can suppress 221 macrophage recruitment or retention during tendon healing. S100a4-RP was shown to drive 222 macrophage migration relative to vehicle, with a significant increase at the highest dose of 1000ng/mL 223 (Fig. 4B ). S100a4-RP treatment of primary macrophages appeared to have a variable impact on 224 polarization. M1 markers iNOS and CD64 were significantly upregulated in a dose-dependent manner 225 following S100a4-RP treatment, while TNFα was downregulated and no change observed in CD86 226 expression (p < 0.05) (Fig. 4C ). M2 markers Arg1 and IL1ra were significantly upregulated with higher 227 doses of RP-S100a4, CD163 was downregulated and no change seen in CD206 (p<0.05) (Fig. 4D) . 228
Collectively this data supports a role for extracellular S100a4 in regulating macrophage migration and 229
polarization. 230 231
Inhibition of S100a4 signaling, via antagonism of RAGE improves tendon healing. 232
Considering that knockdown of S100a4 expression improves healing, and S100a4 can function as an 233 extracellular signaling molecule to drive fibrotic progression (24-26), we next examined expression of 234 the putative S100a4 receptor, RAGE (Receptor for Advanced Glycation Endproducts) (27-29). RAGE 235 expression was observed throughout the scar tissue during tendon healing, with abundant co-236 localization of S100a4 and RAGE (Fig. 4A) . Consequently, we investigated the feasibility of inhibiting 237 S100a4 signaling via disruption of S100a4-RAGE interaction using RAGE antagonist peptide 238 (RAP)(30). In vivo, RAP treatment (Fig. 5B ) significantly improved measures of gliding function relative 239 to vehicle treated controls, with a 41% increase in MTP Flexion Angle (p=0.008) (Fig. 5C) , and a 39% 240 decrease in Gliding Resistance (p=0.007) (Fig. 5D ). No differences in maximum load at failure (p=0.57) 241 and stiffness (p=0.30) were observed between groups (Fig. 5E, F) . These data suggest that inhibition of 242 S100a4-RAGE recapitulates the improvements in gliding function seen with S100a4 haploinsufficiency 243 but is insufficient to improve mechanical properties. 244
245
S100a4
+ cell ablation results in aberrant matrix deposition during tendon healing. 246
While knock-down of S100a4 expression and inhibition of S100a4 signaling improves tendon healing, 247 S100a4 can also function in a cell-autonomous manner (31). To determine the effects of S100a4 + cell 248 ablation on tendon healing, we depleted proliferating S100a4 + cells from D5-10 post-surgery 249 (immediately preceding peak S100a4 expression) (Fig. 6A) . Depletion of S100a4 + cells from D5-10 250 resulted in a significant 91% reduction in S100a4 mRNA expression (p<0.001) (Fig. 6B) , and a 251 substantial reduction in S100a4 protein expression, relative to WT (Fig. 6C) . Functionally, slight but 252 non-significant improvements in gliding function were observed in S100a4-TK (D5-10), relative to WT 253 ( Fig. 6D & E) . However, max load at failure was significantly decreased by 43% (p=0.02) (Fig. 6F) , 254 while stiffness was unchanged (Fig. 6G) . Morphologically, S100a4-TK (D5-10) tendons healed with 255 thinner, more acellular bridging scar tissue between the native tendon ends, compared to the larger, 256 more cellular granulation tissue in WT repairs ( Figure 6H ). Picrosirius staining demonstrated a 257 substantial reduction in bridging ECM in S100a4-TK (D5-10) repairs, relative to WT (Fig. 6I) . In contrast 258 to this, qPCR revealed significant increases in ECM proteins Col1a1 (3.9-fold, p=0.04) (Supplemental 259 Figure 3A) and Col3a1 (1.9-fold, p=0.033) (Supplemental Figure 3B ) mRNA expression in S100a4-TK 260 (D5-10) mice. Additionally, significant decreases in the tenogenic transcription factor Scx (1.75-fold, 261 p=0.04), and the myofibroblast marker a-SMA (9-fold, p=0.0003) were observed in S100a4-TK (D5-10), 262 relative to WT (Supplemental Figure 3C & D) . Consistent with this, and the phenotype in S100a4 GFP/+ 263 repairs, a-SMA staining was markedly reduced in S100a4-TK (D5-10) repairs, relative to WT 264 (Supplemental Figure 4) , as was total macrophage content (Supplemental Figure 5) . Taken together, 265 S100a4-cell depletion alters normal matrix deposition during tendon healing, leading to pronounced 266 morphological changes in the scar tissue and a loss of overall strength, while recapitulating the 267 changes in myofibroblast and macrophage populations observed in S100a4 GFP/+ repairs. 268
We then investigated the effect of continuous S100a4 cell depletion (D1-14) on healing ( Figure 7A ). In 270 contrast to depletion from D5-10, depletion from D1-14 significantly reduced MTP Flexion Angle (-53%, 271 p=0.0003) (Fig. 7B) , and increased gliding resistance (+187%, p<0.001) (Fig. 7C) , indicating 272 impairment of normal gliding function with sustained S100a4 + cell depletion. Consistent with D5-10 273 depletion, depletion from D1-14 reduced mechanical properties, with a 43% decrease in max load 274 (p=0.025) (Fig. 7D) , and a 49% decrease in stiffness (p=0.0078) (Fig. 7E) . 275 276 S100a4-lineage cells represent differentiated a-SMA myofibroblasts in the scar tissue of healing 277
tendon. 278
Examination of S100a4 GFP/+ and S100a4-TK (D5-10) healing tendons demonstrate dramatically reduced 279 myofibroblast content, suggesting potential interplay between these populations. The relationship 280 between S100a4 and pro-fibrotic myofibroblasts is controversial and likely tissue-dependent, with 281 conflicting reports of myofibroblast fate for S100a4 + cells(32-35). To understand the relationship 282 between these cell populations during tendon healing we examined α-SMA expression in both S100a4-283 lineage cells and cells actively expressing S100a4. S100a4-Cre; Ai9 mice demonstrate that most α-284
SMA
+ myofibroblasts at D14 post-surgery are derived from S100a4-lineage, as shown by co-285 localization (Fig. 8A, arrows) . In contrast, very few S100a4 active+ cells demonstrated co-localization with 286 α-SMA (Fig. 8B) . Taken together these data suggest that S100a4-lineage cells lose S100a4 expression 287 during the transition to α-SMA + myofibroblasts. 288
289
Discussion 290
Consistent with the role of S100a4 as a key driver of fibrosis (5, 14, 26, 36), we have demonstrated that 291 S100a4 promotes scar-mediated tendon healing via cell-non-autonomous extracellular signaling. 292
Further, we have shown that knockdown of S100a4 expression drives regenerative tendon healing and 293 that depletion of S100a4 + cells disrupts re-acquisition of mechanical properties. Interestingly, the 294 effects of S100a4 + cell depletion on functional metrics were time-dependent, suggesting a period of 295 optimal S100a4 inhibition. Mechanistically, S100a4 interacts with RAGE and modulates macrophagecontent and function, suggesting the ability of S100a4 to regulate the inflammatory milieu during tendon 297 healing. In addition, S100a4-lineage cells lose expression of S100a4 to become α-SMA + pro-fibrotic 298 myofibroblasts, which are likely involved in both restoration of matrix integrity and deposition of excess 299 ECM. Taken together, these data establish S100a4 haploinsufficiency as a novel model of 300 regenerative, mechanically superior tendon healing, and identify S100a4 as a potent anti-fibrotic 301 therapeutic candidate to improve tendon healing. 302 303 S100a4 lacks enzymatic activity and functions predominantly through the regulation and interaction with 304 other proteins. While the intracellular functions of S100a4 are not well-characterized, the extracellular 305 signaling functions of S100a4 include regulation of multiple cellular processes important in fibrosis 306 including motility (37, 38), differentiation (39-41) and survival (39). S100a4 protein levels are strongly 307 correlated with idiopathic pulmonary fibrosis(34), and S100a4 has been suggested as a potential 308 fibrotic biomarker in the liver (4). Consistent with this, we see highest S100a4 expression immediately 309 prior to the period of peak scar formation during tendon healing. The therapeutic potential of targeting 310 S100a4 has been well established in the lung, with decreased fibrotic progression following treatment 311 with an S100a4 neutralizing antibody (34), and pharmacological inhibition of S100a4 (42). Moreover, 312
Tomcik et al., demonstrated that deletion of S100a4 prevented bleomycin-induced skin fibrosis(26). 313
Consistent with these studies we demonstrated the knock-down of S100a4 is sufficient to attenuate 314 scar-mediated tendon healing and promote a more regenerative response. More specifically, 315
S100a4
GFP/+ repairs demonstrate suppression of multiple components of the fibrotic cascade including 316 macrophage content, myofibroblasts, as well as an altered ECM balance toward a mature tendon 317
composition (Col1a1> Col3a1). 318 319
Macrophages play an essential role in wound healing, and S100a4 is a potent chemokine and regulator 320 of macrophage chemotaxis. Bone marrow-derived macrophages from S100a4 -/-mice display defects in 321 chemotactic motility and impaired recruitment to the site of inflammation (43). While we have not 322 assessed the effects of S100a4 knockdown in macrophages, we have demonstrated that S100a4 alters 323 macrophage migration and polarization in vitro and have shown that macrophage content is markedly 324 reduced in S100a4 haploinsufficient and S100a4 + cell-depleted repairs, suggesting a potential role for 325 extracellular S100a4 in macrophage recruitment during tendon healing. Moreover, while RAGE can be 326 expressed on a variety of cell types, macrophages have been shown to be the primary source of RAGE 327 in the context of pathology (44-47). Therefore, in addition to decreasing the macrophages content, and 328 thereby RAGE + cells, S100a4 GFP/+ may also suppress signaling via direct down-regulation of RAGE. 329 RAGE expression is highly dependent on ligand concentration (48), and we have decreased S100a4 330 expression by 50%, implying down-regulation of the entire S100a4-RAGE-macrophage axis in 331
S100a4
GFP/+ mice. Interestingly, although inhibition of S100a4-RAGE with RAP recapitulates the 332 improvements in gliding function observed in S100a4 GFP/+ repairs, it is insufficient to improve 333 mechanical properties. This suggests that S100a4 may regulate restoration of mechanical properties 334 through mechanisms independent of RAGE. In addition to RAGE, S100a4 can interact with EGFR (49) 335 , Heparan Sulfate Proteoglycans (50), TLR4 (51) and Annexin 2 (52) receptors. However, these 336
S100a4-receptor interactions have been primarily observed in metastasis and neurological disorders. 337
Understanding the potential RAGE independent mechanisms of S100a4 signaling will be an important 338 aspect of future research. 339
340
S100a4
+ cell depletion has shown great efficacy in managing fibrotic progression in the peritoneum 341 (10), and kidney (9). In contrast, depletion of S100a4 + cells impairs tendon healing, particularly when 342
+ cells are depleted from D1-14. These opposing effects may be due to fundamental 343 differences in the functions of affected tissues, with tendon being a mechanical, load-bearing tissue. 344
Interestingly, the more pronounced negative effect of cell depletion from D1-14, relative to D5-10 345 depletion may be explained by suppression of the acute inflammatory phase. Anti-inflammatory 346 administration during the acute inflammatory phase of tendon healing is effective at reducing scar 347 formation, but causes marked reductions in mechanical properties (53-55). Taken together, these data 348 further support the importance of timing treatment to modulate fibrotic tendon healing, particularly as it 349 relates to S100a4 inhibition. population is largely negative for S100a4. These data not only define a terminal myofibroblast fate for 360 many S100a4-lineage cells during tendon healing, but further support the concept of exquisite cell and 361 tissue specificity of S100a4 signaling. In addition to terminal cell fate, the origin of S100a4 + cells are 362 unclear. Osterreicher et al., demonstrate that bone marrow derived cells (BMDCs) represent the main 363 source of S100a4 during liver fibrosis (56), and S100a4 + BMDCs have been shown to migrate to the 364 site of neointima formation following vein grafting (57). While we have not traced S100a4 + BMDCs in 365 this study, we have previously shown specific recruitment of BMDCs to the healing tendon (58), and we 366 also see S100a4
Lin+ and S100a4 active+ populations in the tendon without injury. Future studies will seek 367 to delineate the relative contribution of S100a4 + cells from different origins to scar-mediated tendon 368
healing. 369 370
While we clearly identify S100a4 haploinsufficiency as a model of regenerative tendon healing, there 371 are several limitations that must be considered. First, we have not investigated whether this signaling 372 paradigm is conserved in other tendons. However, we do observe S100a4 + cells in the Achilles tendon 373 at homeostasis and expansion of this population following injury, and since scar-mediated healing is 374 consistent between tendons(59), this reinforces the potential application of this approach to improve 375 healing in multiple tendons. Second, the long-term effects of inhibiting S100a4-RAGE signaling are 376 unknown, as we have only examined healing at D14. However, peak expression of S100a4 at D10 377 post-surgery suggests the prime effects of S100a4 may occur during the early inflammatory/matrix 378 deposition phases of healing. Moreover, the time-dependent effects of S100a4-cell depletion suggestthere is likely an optimal therapeutic window for S100a4 inhibition, which will be examined in future 380 studies. Finally, we have not delineated between the effects of S100a4 expression in resident tendon 381 cells relative to expression in extrinsic cells, and how the cell origin of S100a4 may dictate the effects 382 on healing. 383
384
Restoring satisfactory function following tendon injury has remained an intractable clinical problem for 385 decades (60). To our knowledge this is the first model of regenerative tendon healing in transgenic 386 mice, defined by improvements in range of motion and mechanics. These data will inform future work to 387 define the pathways down-stream of S100a4-RAGE, rigorously determine the time-dependent effects of 388 S100a4 inhibition and identify the cues that drive the transition of S100a4-lineage cells to 389 myofibroblasts. More directly however, these studies define the tremendous potential of inhibition of 390 S100a4 signaling as a therapeutic approach to promote regenerative tendon healing. 391 
